Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RXST
SellRxSight, Inc. · Healthcare · United States · $293M · Avg Vol: $7M/d
COMPANY DESCRIPTION
RxSight, Inc. develops and commercializes the Light Adjustable Lens™ (LAL) system, a proprietary intraocular lens and light delivery device designed for cataract surgery that allows post-operative adjustment of the lens power. This innovative technology provides a distinct competitive advantage in the premium IOL market by addressing residual refractive errors, positioning RxSight as a niche leader in enhancing post-cataract surgery visual outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 49.0M | 89.1M | 139.9M | 134.5M | 40.0% | 127.6M | 147.3M | 149.4M | 5.4% |
| EPS | -2.41 | -1.41 | -0.71 | -0.95 | — | -1.14 | -0.67 | -0.67 | — |
| Shares | 28.3M | 36.1M | 40.4M | 41.2M | +45.9% | 41.6M | — | — | — |
| Debt | 45.0M | 3.0M | 12.3M | 11.0M | -37.4% | 10.6M | — | — | — |
| Equity | 89.9M | 160.4M | 281.2M | 275.7M | 45.3% | — | — | — | — |
| Op CF | -58.9M | -41.6M | -16.9M | -15.5M | — | -22.7M | — | — | — |
| Inv CF | 40.0M | -22.1M | -99.3M | 16.9M | — | — | — | — | — |
| Fin CF | 6.3M | 61.5M | 123.3M | 1.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RXST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RXST | RxSight, Inc.(you) | $293M | 23 | Sell |
| TLSI | TriSalus Life Sciences, Inc. | $297M | 20 | Strong Sell |
| LAB | Standard BioTools Inc. | $252M | 18 | Strong Sell |
| OFIX | Orthofix Medical Inc. | $392M | 28 | Sell |
| CV | CapsoVision, Inc. | $297M | 12 | Strong Sell |
| MOBI | Mobia Medical, Inc. | $378M | 16 | Strong Sell |
| SENS | Senseonics Holdings, Inc. | $493M | 25 | Sell |
| CATX | Perspective Therapeutics, Inc. | $355M | 14 | Strong Sell |
| PACB | Pacific Biosciences of California, Inc. | $435M | 17 | Strong Sell |
| STIM | Neuronetics, Inc. | $224M | 34 | Sell |
Peer medians: ROE -25.0% · P/E 31.0x · Gross margin 58.8%